Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response

[1]  Athanassios Argiris,et al.  Synergistic Interactions between Tamoxifen and Trastuzumab (Herceptin) , 2004, Clinical Cancer Research.

[2]  Jiang Shou,et al.  Cross-Talk between Estrogen Receptor and Growth Factor Pathways as a Molecular Target for Overcoming Endocrine Resistance , 2004, Clinical Cancer Research.

[3]  R. Nicholson,et al.  Nonendocrine Pathways and Endocrine Resistance , 2004, Clinical Cancer Research.

[4]  C. Dabrosin,et al.  Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer in vivo. , 2003, Cancer research.

[5]  R. Gelber,et al.  Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IV. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  L. Rydén,et al.  Tumor Specific VEGF-A and VEGFR2/KDR Protein are Co-expressed in Breast Cancer , 2003, Breast Cancer Research and Treatment.

[7]  M. Tonato,et al.  Evaluation of the Prognostic Role of Vascular Endothelial Growth Factor and Microvessel Density in Stages I and II Breast Cancer Patients , 2003, Breast Cancer Research and Treatment.

[8]  B. Fenton,et al.  Overexpression of vascular endothelial growth factor by MCF-7 breast cancer cells promotes estrogen-independent tumor growth in vivo. , 2003, Cancer research.

[9]  D. Coradini,et al.  Vascular endothelial growth factor in node-positive breast cancer patients treated with adjuvant tamoxifen , 2003, British Journal of Cancer.

[10]  Maxime P Look,et al.  Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  G. Hortobagyi,et al.  Growth factor receptors in breast cancer: potential for therapeutic intervention. , 2003, The oncologist.

[12]  E. Scarpi,et al.  Vascular endothelial growth factor and prognosis in patients with node‐negative breast cancer , 2002, International journal of cancer.

[13]  Simak Ali,et al.  Endocrine-responsive breast cancer and strategies for combating resistance , 2002, Nature Reviews Cancer.

[14]  T. H. van der Kwast,et al.  High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. , 2001, Cancer research.

[15]  R Yancik,et al.  Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. , 2001, JAMA.

[16]  G. Stancel,et al.  Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. , 2000, Cancer research.

[17]  E. Kay,et al.  Immunohistochemical measurement of tumor vascular endothelial growth factor in breast cancer. A more reliable predictor of tumor stage than microvessel density or serum vascular endothelial growth factor. , 2000, Applied immunohistochemistry & molecular morphology : AIMM.

[18]  R. Henriksson,et al.  Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  T. Veikkola,et al.  Regulation of angiogenesis via vascular endothelial growth factor receptors. , 2000, Cancer research.

[20]  S. Tsao,et al.  Co-expression of vascular endothelial growth factor (VEGF) and its receptors (flk-1 and flt-1) in hormone-induced mammary cancer in the Noble rat , 1999, British Journal of Cancer.

[21]  T. Mattfeldt,et al.  Molecular mediators of tumor angiogenesis: Enhanced expression and activation of vascular endothelial growth factor receptor KDR in primary breast cancer , 1999, International journal of cancer.

[22]  P. Vermeulen,et al.  Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. , 1999, The cancer journal from Scientific American.

[23]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[24]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[25]  C. Osborne,et al.  Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu , 1992, Breast Cancer Research and Treatment.

[26]  R. Gelber,et al.  Adjuvant systemic therapy for breast cancer in the elderly: competing causes of mortality. International Breast Cancer Study Group. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  M. Toi,et al.  Tumor angiogenesis in breast cancer: Its importance as a prognostic indicator and the association with vascular endothelial growth factor expression , 2004, Breast Cancer Research and Treatment.